German pharma Bill "won't cut drug costs" as IQWiG ups staffing by a third
This article was originally published in Scrip
Executive Summary
Dr Andreas Gerber, head of the department for health economics at Germany's health technology assessment body, the Institute for Quality and Efficiency in Health Care (IQWiG), has questioned the role of the AMNOG Bill, which is re-organising the pharmaceutical sector and is expected to be passed today (11 November), saying it will not slow down growth in drug costs.